Safety and effectiveness in an uncontrolled setting of glucagon‐like‐peptide‐1 receptor agonists in patients with familial partial lipodystrophy: Real‐life experience from a national reference network

GLP-1RA significantly improved BMI, HbA1c and triglycerides in a large majority of patients with FPLD. Larger and prospective controlled studies are warranted for identification of predictive factors and safety.